MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue GuidanceGlobeNewsWire • 11/12/25
MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue GuidanceGlobeNewsWire • 11/05/25
MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid TumorsGlobeNewsWire • 10/06/25
MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to ProfitabilityGlobeNewsWire • 09/22/25
MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy PipelineGlobeNewsWire • 07/31/25
MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular TherapiesGlobeNewsWire • 06/11/25
MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 GuidanceGlobeNewsWire • 05/07/25
Down -27.78% in 4 Weeks, Here's Why You Should You Buy the Dip in MaxCyte (MXCT)Zacks Investment Research • 04/08/25
Down -30.2% in 4 Weeks, Here's Why MaxCyte (MXCT) Looks Ripe for a TurnaroundZacks Investment Research • 04/07/25
MaxCyte: Strong Revenues, Fast-Growing Cell-Therapy Market, Very Low Share PriceSeeking Alpha • 03/15/25
MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 GuidanceGlobeNewsWire • 03/11/25
MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics ProgramsGlobeNewsWire • 02/12/25
MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor ConferenceGlobeNewsWire • 02/07/25